Vaccine, tetanus toxoid, tetanus toxoid adsorbed: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the local prescribing information.

Generic Medicine Info

Indications and Dosage

Intramuscular
Active immunisation against tetanus

Adult: Primary immunisation: 3 or 4 doses of 0.5 mL each, with dosing intervals depending on the product used. Booster dose: 0.5 mL every 10 years.
Child: Primary immunisation: ≥6-8 weeks Same as adult dose.

Intramuscular
Prophylaxis of tetanus in wound management

Adult: Non-immunised patients, or if >5-10 years since last booster dose: 1 emergency dose of 0.5 mL, depending on the type of wound. Patients with minor, clean wounds who have been vaccinated within the last 5-10 years may not need emergency booster dose.

Contraindications

Hypersensitivity. Neurological disorders following previous vaccination.

Special Precautions

Patient with coagulation/bleeding disorders (e.g. thrombocytopenia), Guillain-Barré syndrome (within 6 weeks prior to receiving vaccination), immunodeficiency (e.g. HIV infection). Patients with complete primary vaccination or a booster dose in the previous 5 years. Postpone vaccination in patients with acute febrile illness. Children. Pregnancy and lactation.

Adverse Reactions

Significant: Syncope.
Blood and lymphatic system disorders: Lymphadenopathy.
Gastrointestinal disorders: Nausea.
General disorders and administration site conditions: Inj site reactions (e.g. pain, redness, bruising, swelling, induration), fever, malaise, irritability.
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Neuritis, headache, dizziness.
Skin and subcutaneous tissue disorders: Rash.
Vascular disorders: Hypotension.
Potentially Fatal: Anaphylactoid or hypersensitivity reactions.

Pregnancy Category (US FDA)

IM/Parenteral/SC: C

MonitoringParameters

Monitor for syncope, hypersensitivity reactions, 15 minutes after administration.

Drug Interactions

Increased risk of bleeding with anticoagulants. Decreased therapeutic effect and immune response with immunosuppressive therapies (e.g. high-dose corticosteroids).

Action

Description: Tetanus toxoid vaccine is a preparation of inactivated toxin produced by virulent tetanus bacilli (product of Clostridium tetani). It acts as antigen and produces active immunity against tetanus.
Duration: Immunity: Approx 10 years.

Storage

Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07AM01 - tetanus toxoid ; Belongs to the class of tetanus bacterial vaccines.

References

Anon. Tetanus Toxoid (Adsorbed). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/08/2018.

Buckingham R (ed). Tetanus Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/08/2018.

Tetavax Multidose and Single Dose Tetanus Vaccine (Sanofi Pasteur). MIMS Singapore. http://www.mims.com/singapore. Accessed 20/08/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, tetanus toxoid, tetanus toxoid adsorbed from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com